000304464 001__ 304464
000304464 005__ 20250909114905.0
000304464 0247_ $$2doi$$a10.1038/s41591-025-03928-9
000304464 0247_ $$2pmid$$apmid:40913172
000304464 0247_ $$2ISSN$$a1078-8956
000304464 0247_ $$2ISSN$$a1546-170X
000304464 037__ $$aDKFZ-2025-01857
000304464 041__ $$aEnglish
000304464 082__ $$a610
000304464 1001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b0$$eFirst author$$udkfz
000304464 245__ $$aMolecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.
000304464 260__ $$a[New York, NY]$$bSpringer Nature$$c2025
000304464 3367_ $$2DRIVER$$aarticle
000304464 3367_ $$2DataCite$$aOutput Types/Journal article
000304464 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757401604_15617
000304464 3367_ $$2BibTeX$$aARTICLE
000304464 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304464 3367_ $$00$$2EndNote$$aJournal Article
000304464 500__ $$a#EA:B320#LA:B320# / epub
000304464 520__ $$aAdvances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (N2M2), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. Stratification for treatment was conducted by a trial-specific molecular tumor board across five subtrials, each evaluating a targeted therapy-alectinib, idasanutlin, palbociclib, vismodegib or temsirolimus-selected according to the best-matching molecular alteration. Patients without matching alterations were randomized between subtrials without strong biomarkers using atezolizumab and asunercept, and the standard of care (SOC), temozolomide. All received radiotherapy. The primary endpoints were dose-limiting toxicities (phase 1) and progression-free survival at 6 months (PFS-6; phase 2). Secondary endpoints included safety and tolerability, as well as overall survival (OS). The subtrials for alectinib and vismodegib did not open as they did not have matching patients. The idasanutlin subtrial (n = 9) was terminated early at the discretion of the manufacturing company. The temsirolimus subtrial (n = 46) demonstrated a PFS-6 of 39.1% and median OS of 15.4 months in patients with activated mammalian target of rapamycin (mTOR) signaling compared to a PFS-6 at 18.5% in the SOC group (n = 54), meeting the primary endpoint. The atezolizumab (n = 42), asunercept (n = 26) and palbociclib (n = 41) subtrials did not meet the primary endpoint for efficacy. The safety signals of N2M2 match prior experiences with the drugs in quality and quantity; no relevant negative interaction with the parallel radiotherapy was noted. The results of the N2M2 trial support further investigation of temsirolimus in addition to radiotherapy in patients with newly diagnosed glioblastoma with activated mTOR signaling. ClinicalTrials.gov registration: NCT03158389 .
000304464 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304464 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304464 7001_ $$0P:(DE-He78)4aed88756bf54245b941fddaa2168ddc$$aLanz, Lisa-Marie$$b1$$udkfz
000304464 7001_ $$0P:(DE-HGF)0$$aWick, Antje$$b2
000304464 7001_ $$aHarting, Inga$$b3
000304464 7001_ $$0P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDettmer, Susan$$b4$$udkfz
000304464 7001_ $$0P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aSuwala, Abigail K$$b5$$udkfz
000304464 7001_ $$aKetter, Ralf$$b6
000304464 7001_ $$aTabatabai, Ghazaleh$$b7
000304464 7001_ $$aSeliger, Corinna$$b8
000304464 7001_ $$aGlas, Martin$$b9
000304464 7001_ $$00000-0002-6927-0987$$aBurger, Michael C$$b10
000304464 7001_ $$aTimmer, Marco$$b11
000304464 7001_ $$aRingel, Florian A$$b12
000304464 7001_ $$0P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3$$aMildenberger, Iris$$b13$$udkfz
000304464 7001_ $$00000-0001-5886-2322$$aSchulz-Schaeffer, Walter J$$b14
000304464 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b15$$udkfz
000304464 7001_ $$aKönig, Laila$$b16
000304464 7001_ $$aHerold-Mende, Christel$$b17
000304464 7001_ $$0P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aEisenmenger, Andreas$$b18$$udkfz
000304464 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b19$$udkfz
000304464 7001_ $$aRenovanz, Mirjam$$b20
000304464 7001_ $$aBendszus, Martin$$b21
000304464 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b22$$udkfz
000304464 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b23$$udkfz
000304464 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b24$$eLast author$$udkfz
000304464 773__ $$0PERI:(DE-600)1484517-9$$a10.1038/s41591-025-03928-9$$pnn$$tNature medicine$$vnn$$x1078-8956$$y2025
000304464 909CO $$ooai:inrepo02.dkfz.de:304464$$pVDB
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4aed88756bf54245b941fddaa2168ddc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7daa75b87e6d6e291016ecb54f60b6b3$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000304464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000304464 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304464 9141_ $$y2025
000304464 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-06$$wger
000304464 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2025-01-06$$wger
000304464 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT MED : 2022$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000304464 915__ $$0StatID:(DE-HGF)9980$$2StatID$$aIF >= 80$$bNAT MED : 2022$$d2025-01-06
000304464 9202_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000304464 9200_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000304464 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000304464 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304464 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x2
000304464 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000304464 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x4
000304464 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x5
000304464 980__ $$ajournal
000304464 980__ $$aVDB
000304464 980__ $$aI:(DE-He78)B320-20160331
000304464 980__ $$aI:(DE-He78)HD01-20160331
000304464 980__ $$aI:(DE-He78)W010-20160331
000304464 980__ $$aI:(DE-He78)B300-20160331
000304464 980__ $$aI:(DE-He78)D170-20160331
000304464 980__ $$aI:(DE-He78)B062-20160331
000304464 980__ $$aUNRESTRICTED